Spontaneous resolution of advanced basal cell carcinoma after short-pulse treatment with hedgehog pathway inhibitor
نویسندگان
چکیده
BCC: basal cell carcinoma HPI: hedgehog pathway inhibitors laBCC: locally advanced basal cell carcinoma RT: radiotherapy INTRODUCTION Hedgehog pathway inhibitors (HPIs) are indicated for locally advanced basal cell carcinoma (laBCC) and metastatic basal cell carcinoma with reported treatment length of 5.5months tomore than 5 years. The definition of laBCC is historically ill described and only recently has a consensus definition been proposed. Treatment is indicated until tumor resistance or adverse events cause interruption. Therefore, we do not know the length of treatment necessary for tumor clearance. We describe a patient who received a single 2-week pulse treatment of HPI therapy and subsequently experienced sustained clinical and histologic clearance of his tumor.
منابع مشابه
Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma
Abnormal activation of hedgehog pathway signaling is a key driver in the pathogenesis of basal cell carcinoma (BCC). Vismodegib, a first-in-class small-molecule inhibitor of hedgehog pathway signaling, is approved by regulatory authorities for the treatment of adults who have metastatic BCC or locally advanced BCC that has recurred after surgery, or who are not candidates for surgery and who ar...
متن کاملEmergence of Squamous Cell Carcinoma during Treatment of Basal Cell Carcinoma with Vismodegib
Basal cell carcinoma (BCC) accounts for 80% of all non-melanoma skin cancer [1]. Advanced disease is infrequently seen, but when present can be a surgical challenge or even life threatening. Recent studies show that mutations in the hedgehog (HH) signaling pathway are associated with the majority of BCC. Hedgehog protein binds to patched homologue 1 (PTCH1) transmembrane receptor, which prevent...
متن کاملSonidegib, a novel smoothened inhibitor for the treatment of advanced basal cell carcinoma
Basal cell carcinoma (BCC) is the most common nonmelanoma skin cancer. If left untreated, BCCs can become locally aggressive or even metastasize. Currently available treatments include local destruction, surgery, and radiation. Systemic options for advanced disease are limited. The Hedgehog (Hh) pathway is aberrantly activated in a majority of BCCs and in other cancers. Hh pathway inhibitors ar...
متن کاملکارسینوم سلول بازال: از مولکول تا درمان
Basal cell carcinoma (BCC) is the most common cancer in Iran and in the world and its prevalence may become equivalent to the prevalence of all other cancers combined in the future. The Hedgehog (Hh) signaling pathway has an important role in tumorigenesis of BCC. Mutations in PTCH and Smo molecules of this pathway account for 85% to 95% of sporadic BCCs and also most cases of inherited cases. ...
متن کاملProfile of vismodegib and its potential in the treatment of advanced basal cell carcinoma
Basal cell carcinoma (BCC) is the most common human malignancy. Recent advances in our understanding of the critical biologic pathways implicated in the development and progression of BCC have led to the development of the first molecular targeted therapy for this disease. The hedgehog pathway is mutated in virtually all patients with BCC and recent trials with vismodegib, an inhibitor of this ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 2 شماره
صفحات -
تاریخ انتشار 2016